Azurity Pharmaceuticals focuses on developing innovative dose-form solutions for established medications, specifically targeting patients with unmet medical needs. The company specializes in creating high-quality medicines across various therapeutic areas, including cardiovascular, central nervous system, endocrine, gastrointestinal, anti-infective, and oncology. Their portfolio includes unique formulations such as oral solutions and suspensions, which are designed to improve patient compliance and accessibility. Notably, Azurity has received FDA approvals for several products, including Danziten™, the first nilotinib without mealtime restrictions, and Nymalize®, an oral solution of nimodipine, showcasing their commitment to addressing the needs of overlooked patient populations.

The company’s product offerings are characterized by their focus on therapeutic innovation, with a range of FDA-approved medications that provide alternatives to traditional dosage forms. Azurity's products, such as EPRONTIA® (topiramate oral solution) and KATERZIA® (amlodipine oral suspension), exemplify their dedication to creating formulations that enhance the delivery and effectiveness of treatments. By continuously expanding their portfolio, Azurity aims to meet the diverse needs of patients suffering from various medical conditions, ensuring that effective treatment options are available for those who may not benefit from existing therapies.

United States

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Azurity Pharmaceuticals

Company Details